These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 39227388)
1. Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study. Zeng Z; Yang A; Yang J; Zhang S; Xing Z; Wang X; Mei W; Jiang C; Lin J; Wu X; Xue Y; Wu Z; Yu L; Wang D; Chen J; Zheng S; Lin Q; Chen Q; Dong J; Zheng X; Wang J; Huang J; Chen Z; Chen P; Zheng M; Zhou X; He Y; Lin Y; Chen J Signal Transduct Target Ther; 2024 Sep; 9(1):229. PubMed ID: 39227388 [TBL] [Abstract][Full Text] [Related]
2. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Bromberg JEC; Issa S; Bakunina K; Minnema MC; Seute T; Durian M; Cull G; Schouten HC; Stevens WBC; Zijlstra JM; Baars JW; Nijland M; Mason KD; Beeker A; van den Bent MJ; Beijert M; Gonzales M; de Jong D; Doorduijn JK Lancet Oncol; 2019 Feb; 20(2):216-228. PubMed ID: 30630772 [TBL] [Abstract][Full Text] [Related]
3. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China. Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418 [TBL] [Abstract][Full Text] [Related]
4. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782 [TBL] [Abstract][Full Text] [Related]
5. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Wong ET; Tishler R; Barron L; Wu JK Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999 [TBL] [Abstract][Full Text] [Related]
6. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Glass J; Won M; Schultz CJ; Brat D; Bartlett NL; Suh JH; Werner-Wasik M; Fisher BJ; Liepman MK; Augspurger M; Bokstein F; Bovi JA; Solhjem MC; Mehta MP J Clin Oncol; 2016 May; 34(14):1620-5. PubMed ID: 27022122 [TBL] [Abstract][Full Text] [Related]
7. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065 [TBL] [Abstract][Full Text] [Related]
8. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644 [TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800 [TBL] [Abstract][Full Text] [Related]
11. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587 [TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235 [TBL] [Abstract][Full Text] [Related]
14. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. Omuro AM; Taillandier L; Chinot O; Carnin C; Barrie M; Hoang-Xuan K J Neurooncol; 2007 Nov; 85(2):207-11. PubMed ID: 17896079 [TBL] [Abstract][Full Text] [Related]
15. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380 [TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate, high-dose cytarabine and temozolomide for the treatment of primary central nervous system lymphoma (PCNSL). Salamoon M; Hussein T; Kenj M; Bachour M Med Oncol; 2013 Dec; 30(4):690. PubMed ID: 23959450 [TBL] [Abstract][Full Text] [Related]
17. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy. Qian L; Zhou C; Shen J; Cen J; Yin W Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056 [TBL] [Abstract][Full Text] [Related]
18. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720 [TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839 [TBL] [Abstract][Full Text] [Related]
20. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Nayak L; Abrey LE; Drappatz J; Gilbert MR; Reardon DA; Wen PY; Prados M; Deangelis LM; Omuro A; Leuk Lymphoma; 2013 Jan; 54(1):58-61. PubMed ID: 22656234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]